1. Articles in category: Treatment

    1-24 of 125 1 2 3 4 5 6 »
    1. Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells.

      Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells.

      Biochem Biophys Res Commun. 2017 Jul 12;:

      Authors: Li Y, Zhuo B, Yin Y, Han T, Li S, Li Z, Wang J

      Abstract Chemotherapy is one of the few effective choices for patients with neuroblastoma. However, the development of muti-drug resistance (MDR) to chemotherapy is a major obstacle to the effective treatment of advanced or recurrent neuroblastoma.

      Read Full Article
    2. Moringa isothiocyanate complexed with α-cyclodextrin: a new perspective in neuroblastoma treatment.

      Moringa isothiocyanate complexed with α-cyclodextrin: a new perspective in neuroblastoma treatment.

      BMC Complement Altern Med. 2017 Jul 14;17(1):362

      Authors: Giacoppo S, Iori R, Rollin P, Bramanti P, Mazzon E

      Abstract BACKGROUND: Several lines of evidence suggest the consume of natural products for cancer prevention or treatment. In particular, isothiocyanates (ITCs) exerting anti-cancer properties, have received great interest as potential chemotherapeutic agents.

      Read Full Article
      Mentions: Treatment LDH
    3. New potential treatment for aggressive types of childhood cancer

      New potential treatment for aggressive types of childhood cancer

      A combination of substances that impacts chemical modifications in the DNA of tumours and triggers the tumours to differentiate into harmless nerve cells could represent a new method of treating aggressive forms of neuroblastoma. The new method has been proposed by researchers at Karolinska Institutet, after studies using mice showed that the combination treatment resulted in a significant suppression in tumour growth.

      Read Full Article
      Mentions: Treatment
    4. Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression.

      Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression.

      Proc Natl Acad Sci U S A. 2017 Jul 10;:

      Authors: Westerlund I, Shi Y, Toskas K, Fell SM, Li S, Surova O, Södersten E, Kogner P, Nyman U, Schlisio S, Holmberg J

      Read Full Article
      Mentions: Treatment MYCN
    5. Metabolic syndrome induced by anticancer treatment in childhood cancer survivors.

      Metabolic syndrome induced by anticancer treatment in childhood cancer survivors.

      Ann Pediatr Endocrinol Metab. 2017 Jun;22(2):82-89

      Authors: Chueh HW, Yoo JH

      Abstract The number of childhood cancer survivors is increasing as survival rates improve. However, complications after treatment have not received much attention, particularly metabolic syndrome.

      Read Full Article
      Mentions: Treatment
    6. Pain in Children with Cancer: Prevalence, Characteristics, and Parent Management.

      Pain in Children with Cancer: Prevalence, Characteristics, and Parent Management.

      Clin J Pain. 2017 Jul 03;:

      Authors: Tutelman PR, Chambers CT, Stinson JN, Parker JA, Fernandez CV, Witteman HO, Nathan PC, Barwick M, Campbell F, Jibb LA, Irwin K

      Abstract OBJECTIVES: Pain is a common and distressing symptom of pediatric cancer, as reported by both children and their parents.

      Read Full Article
    7. Treatment of Transient Peripheral Neuropathy During Chimeric 14.18 Antibody Therapy in Children With Neuroblastoma: A Case Series.

      Treatment of Transient Peripheral Neuropathy During Chimeric 14.18 Antibody Therapy in Children With Neuroblastoma: A Case Series.

      J Pediatr Hematol Oncol. 2017 Jul 03;:

      Authors: Ari P, Kars M, Meany H, Pestieau S

      Abstract Children with high-risk neuroblastoma are currently treated with a chimeric monoclonal antibody against GD2 ganglioside (chimeric 14.18). The treatment improves survival but causes transient neuropathic pain-like syndrome.

      Read Full Article
      Mentions: Antibody Treatment
    8. Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALK(F1174L) Drug-Resistant Neuroblastoma Preclinical Models.

      Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALK(F1174L) Drug-Resistant Neuroblastoma Preclinical Models.

      Transl Oncol. 2017 Jun 27;10(4):604-611

      Authors: Zhang L, Wu B, Baruchel S

      Abstract BACKGROUND: Anaplastic lymphoma kinase (ALK) inhibitor crizotinib has proven to be effective in the treatment of ALK-mutated neuroblastoma, but crizotinib resistance was commonly observed in patients.

      Read Full Article
      Mentions: Treatment ALK
    9. Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome.

      Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome.

      Pediatr Neurol. 2017 May 19;:

      Authors: Pranzatelli MR, Tate ED

      Abstract BACKGROUND: Although pulse-dose dexamethasone is increasingly favored for treating pediatric opsoclonus-myoclonus syndrome (OMS), and multimodal immunotherapy is associated with improved clinical response, there have been no neuroimmunologic studies of dexamethasone-based multimodal disease-modifying therapy. METHODS: In this observational retrospective study, 19 children with OMS (with or without associated neuroblastoma) underwent multibiomarker evaluation for neuroinflammation. Nine children of varying OMS severity, duration, and treatment status were treated empirically with pulse dexamethasone, intravenous immunoglobulin (IVIg), and rituximab combination immunotherapy (DEXIR-CI). Another ...

      Read Full Article
    10. Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.

      Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.

      Pediatr Blood Cancer. 2017 May;64(5):

      Authors: Jiménez I, Baruchel A, Doz F, Schulte J

      Abstract The last few years have seen the identification of pharmacologic approaches to target bromodomain and extraterminal (BET) proteins for cancer treatment.

      Read Full Article
      Mentions: Treatment
    11. The role of surgery in delayed local treatment for INSS 4 neuroblastoma.

      The role of surgery in delayed local treatment for INSS 4 neuroblastoma.

      Pediatr Int. 2017 Jun 23;:

      Authors: Uehara S, Yoneda A, Oue T, Nakahata K, Zenitani M, Miyamura T, Hashii Y, Fukuzawa M, Okuyama H

      Abstract PURPOSE: The aim of the present study was to compare the efficacy, complications and outcomes of the following two different surgical strategies, in patients receiving delayed local treatment for INSS 4 neuroblastoma (NB): complete resection (CR; period A), and gross total resection (GTR)/subtotal resection (STR) with local irradiation (period B). METHODS: We retrospectively analyzed 17 patients with INSS 4 neuroblastoma (NB) who ...

      Read Full Article
      Mentions: Treatment Surgery
    12. New research points to potential targeted treatments of neuroblastoma tumours

      New research points to potential targeted treatments of neuroblastoma tumours

      Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research by the University of Chicago Medicine.

      The findings lay the groundwork for developing more targeted treatments for...

      Read Full Article
      Mentions: MYCN
    13. Potential for more targeted treatments of neuroblastoma tumors

      Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research. The findings lay the groundwork for developing more targeted treatments for particularly deadly variations of the cancer.

      Read Full Article
      Mentions: MYCN
    14. New research points to potential for more targeted treatments of neuroblastoma tumors

      New research points to potential for more targeted treatments of neuroblastoma tumors

      ( University of Chicago Medical Center ) Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research by the University of Chicago Medicine. The findings lay the groundwork for developing more targeted treatments for particularly deadly variations of the cancer.

      Read Full Article
      Mentions: MYCN
    15. Giving children a voice in clinical trials

      Giving children a voice in clinical trials

      ( Children's National Health System ) Children as young as 8 years old with incurable cancer can reliably characterize the impact an experimental therapy has on their symptoms and quality of life -- even at the earliest stages of drug development -- making self-reported patient outcomes a potential new clinical trial endpoint.

      Read Full Article
    16. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.

      "Thirty-nine of 451 evaluable tumors (9%) expressed PD-L1 in at least 1% of tumor cells. The highest frequency histotypes comprised Burkitt lymphoma (80%; 8 of 10 tumors), glioblastoma multiforme (36%; 5 of 14 tumors), and neuroblastoma (14%; 17 of 118 tumors). PD-L1 staining was associated with inferior survival among patients with neuroblastoma (P = .004). Seventy-four percent of tumors contained lymphocytes and/or macrophages. Macrophages were significantly more likely to be identified in PD-L1-positive versus PD-L1-negative tumors (P < .001).  A subset of diagnostic pediatric cancers exhibit PD-L1 expression, whereas a much larger fraction demonstrates infiltration with tumor-associated lymphocytes. PD-L1 expression may ...

      Read Full Article
      Mentions: PD-1
    17. Car T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.

      "Targeting disialoganglioside (GD2) on neuroblastoma (NB) with T cells expressing a first-generation chimeric antigen receptor (CAR) was safe, but the cells had poor expansion and long-term persistence. We developed a third-generation GD2-CAR (GD2-CAR3) and hypothesized that GD2-CAR3 T cells (CARTs) would be safe and effective. This phase 1 study enrolled relapsed or refractory NB patients in three cohorts. Cohort 1 received CART alone, cohort 2 received CARTs plus cyclophosphamide and fludarabine (Cy/Flu), and cohort 3 was treated with CARTs, Cy/Flu, and a programmed death-1 (PD-1) inhibitor. Eleven patients were treated with CARTs. The infusions were safe, and no ...

      Read Full Article
      Mentions: PD-1
    18. Precision Medicine in Pediatric Oncology: Translating Genomic Discoveries into Optimized Therapies.

      "Survival of children with cancers has dramatically improved over the past several decades.  This success has been achieved through improvement of combined modalities in treatment approaches, intensification of cytotoxic chemotherapy for those with high-risk disease and refinement of risk stratification incorporating novel biologic markers in addition to traditional clinical and histologic features. Advances in cancer genomics have shed important mechanistic insights on disease biology and have identified "driver" genomic alterations, aberrant activation of signaling pathways, and epigenetic modifiers that can be targeted by novel agents.  Thus, the recently described genomic and epigenetic landscapes of many childhood cancers have expanded the ...

      Read Full Article
    19. Improved outcome of (131)I-mIBG treatment through combination with external beam radiotherapy in the SK-N-SH mouse model of neuroblastoma.

      Improved outcome of (131)I-mIBG treatment through combination with external beam radiotherapy in the SK-N-SH mouse model of neuroblastoma.

      Radiother Oncol. 2017 Jun 05;:

      Authors: Corroyer-Dulmont A, Falzone N, Kersemans V, Thompson J, Allen DP, Able S, Kartsonaki C, Malcolm J, Kinchesh P, Hill MA, Vojnovic B, Smart SC, Gaze MN, Vallis KA

      Read Full Article
    20. Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors.

      Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors.

      Pediatr Hematol Oncol. 2017 Jun 07;:1-10

      Authors: Clemens E, de Vries AC, Am Zehnhoff-Dinnesen A, Tissing WJ, Loonen JJ, Pluijm SF, van Dulmen-den Broeder E, Bresters D, Versluys B, Kremer LC, van der Pal HJ, Neggers SJ, van Grotel M, M van den Heuvel-Eibrink M

      Read Full Article
    21. YmAbs Announces Positive Topline Result in Pivotal Study of burtomab in Refractory Leptomeningeal Metastasis from Neuroblastoma

      YmAbs Announces Positive Topline Result in Pivotal Study of burtomab in Refractory Leptomeningeal Metastasis from Neuroblastoma

      "Y-mAbs Therapeutics, Inc. (YmAbs), an immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced positive top line results from a pivotal study of 131I-burtomab in Refractory Leptomeningeal Metastasis from Neuroblastoma. Results showed a 58 months average survival for the patients treated with 131I-burtomab in the study, compared to an average of 4.7 month and no long term survival or cure, for a contemporary cohort in the Central German Childhood Cancer Registry. After more than a decade of follow-up, data shows more than 40% overall long term survival indicating that the treated children have ...

      Read Full Article
    22. Results Indicate That Larotrectinib Is Effective as the First Novel Targeted Therapy to Show a Consistent Response across Multiple Tumor Types in Adult and Pediatric Patients

      Results Indicate That Larotrectinib Is Effective as the First Novel Targeted Therapy to Show a Consistent Response across Multiple Tumor Types in Adult and Pediatric Patients

      Larotrectinib (LOXO-101) has demonstrated consistent and durable antitumor activity in tropomyosin receptor kinase (TRK) fusion cancers across a wide range of patient ages and tumor types and was well tolerated by patients, according to results from three clinical trials presented today at the annual meeting of the American Society of Clinical Oncology in Chicago.

      Read Full Article
    23. Chronic health conditions among long-term survivors of childhood cancer decrease over three decades as treatments improve

      Chronic health conditions among long-term survivors of childhood cancer decrease over three decades as treatments improve

      MEMPHIS, Tenn., June 2, 2017 /PRNewswire/ -- Changes in the treatment of pediatric cancer over recent decades have translated to a reduced risk of serious, long-term late health effects of cancer therapy. This is according to the latest analysis from the Childhood Cancer Survivor Study (CC...

      Read Full Article
      Mentions: Treatment
    1-24 of 125 1 2 3 4 5 6 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (2 articles) MYCN
    2. (1 articles) Antibody
    3. (1 articles) Immunotherapy
    4. (1 articles) LDH
    5. (1 articles) ALK
  4. General Informations in the News

    1. (10 articles) Treatment
  5. Treatments in the News

    1. (1 articles) Surgery
    2. (1 articles) Chemotherapy